Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

19 nov. 2024 09h00 HE | Source: Georgiamune Inc.

Georgiamune Appoints Biopharma Veteran Mark Avagliano as Chief Business Officer to Drive Growth

GAITHERSBURG, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announces the appointment of Mark Avagliano as Chief Business...
24 sept. 2024 09h00 HE | Source: Georgiamune Inc.

Georgiamune Announces First Participant Dosed in First-In-Class Phase 1 Healthy Volunteers Trial of GIM-407

GAITHERSBURG, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced that the first participant has been dosed with...
30 juil. 2024 09h00 HE | Source: Georgiamune Inc.

Georgiamune Announces First Patient Dosed in A First-In-Class Phase 1 Cancer Treatment Trial of GIM-531

GAITHERSBURG, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced that the first patient has been dosed with GIM-531 in...
29 mai 2024 10h40 HE | Source: Georgiamune Inc.

UPDATE -- Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of Launch

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced the clearance of its second Investigational New Drug...
29 mai 2024 09h00 HE | Source: Georgiamune Inc.

Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of Launch

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced the clearance of its second Investigational New Drug...